Arcturus Therapeutics Holdings, Inc. (ARCT)
7.46
-0.06
(-0.80%)
USD |
NASDAQ |
Dec 12, 16:00
7.45
-0.01
(-0.13%)
After-Hours: 20:00
Arcturus Therapeutics Holdings Research and Development Expense (Quarterly): 19.38M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | 12.98M |
| Novavax, Inc. | 98.17M |
| Sangamo Therapeutics, Inc. | 28.69M |
| Capricor Therapeutics, Inc. | 20.11M |
| AIM ImmunoTech, Inc. | 0.525M |